More articles from Current Drug Therapy
- Advances in cluster headache management
Cluster headache is often misdiagnosed, and, until recently, therapy was difficult. Verapamil has revolutionized treatment.
- The clinical role of platelet glycoprotein Ilb/IIIa receptor inhibitors in ischemic heart disease
These new drugs show great promise in reducing the complications of angioplasty and acute coronary syndromes.
- Lipid-regulating and antiatherosclerotic therapy: current options and future approaches
New strategies for regulating lipids, such as new drugs and gene therapy, hold promise in reducing coronary heart disease, but current guidelines are still the first, best strategy.
- Methotrexate in rheumatoid arthritis: when NSAIDs fail
With diligent monitoring, low-dose methotrexate is effective for treating selected patients with rheumatoid arthritis, and it is safer than previously thought.
- Use of old and new oral 5-aminosalicylic acid formulations in inflammatory bowel disease
Sulfasalazine, a 5-ASA agent, is the anti-inflammatory agent of choice for ulcerative colitis and Crohn's disease. Newer delayed-release formulations can also be appropriate first-line agents.
- Drugs for the prevention and treatment of acute renal failure
Mannitol, loop diuretics, dopamine, and calcium antagonists show promise, but they have not yet been rigorously tested for this indication. Caution is advised.
- Advances in migraine management
New drugs and a better understanding of migraine's pathogenesis are improving the outlook for patients with this debilitating disorder.